Strain Information | |
---|---|
Image | |
BRC No. | RBRC01708 |
Type | Transgene |
Species | Mus musculus |
Strain name | B6.Cg-Tg(Mt1-RET)242Ina |
Former Common name | 242 RET |
H-2 Haplotype | |
ES Cell line | |
Background strain | |
Appearance | |
Strain development | Developed by Masashi Kato, Nagoya University Graduate School of Medicine. The Mt1-RET transgene was injected into the fertilized eggs of (BALB/c x C57BL/6) x BALB/c mice. C57BL/6 and BALB/c mixed background. |
Strain description | Mt1-Ret 242 transgenic mice. The mice express the human RET under the control of the mouse MT1 promoter/enhancer. Mt1-RET homozygous mutant mice are embryonic lethal. |
Colony maintenance | Carrier x Noncarrier |
References | Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a metallothionein/ret fusion gene. Iwamoto T, Takahashi M, Ito M, Hamatani K, Ohbayashi M, Wajjwalku W, Isobe K, Nakashima I EMBO J., 10, 3167-3175 (1991). 1915289 |
Health Report | |
---|---|
Examination Date / Room / Rack |
Gene | |||||||
---|---|---|---|---|---|---|---|
Gene Symbol | Gene Name | Chr. | Allele Symbol | Allele Name | Common Names | Promoter | Diseases Related to This Gene |
SV40 splicing signal-polyadenylation site | UN | ||||||
RET | recombinant RET proto-oncogene (human) | UN | RET | mouse metallothionein 1 promoter/enhancer | |||
Tg(Mt1-RET)242Ina | transgene insertion 242, Izumi Nakashima | UN | Tg(Mt1-RET)242Ina |
Phenotype | |
---|---|
Annotation by Mammalian phenotyhpe ontology | |
Detailed phenotype data |
Ordering Information | |
---|---|
Donor DNA | human RFP/RET cDNA, mouse MT-I promoter-enhancer, SV40 splicing signal-polyadenylation site, vector sequence |
Research application | Cancer Research Dermatology Research Mouse Models for Human Disease |
Specific Term and Conditions | The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. The RECIPIENT of BIOLOGICAL RESOURCE must obtain a prior written consent on use of it from the DEPOSITOR/DEVELOPER. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use with the results from the use of the BIOLOGICAL RESOURCE. The RECIPIENT agrees to use this BIOLOGICAL RESOURCE as a collaboration with the DEPOSITOR. |
Depositor | Masashi Kato (Chubu University) |
Strain Status | Frozen embryos |
Strain Availability | Recovered litters from cryopreserved embryos (2 to 4 months) Cryopreserved embryos (within 1 month) |
Additional Info. | Necessary documents for ordering:
Genotyping protocol -PCR- |
BRC mice in Publications |
---|
No Data |